For the Inventor, By the Inventor

Enter assignee name

Hazelwood, MO, United States of America

Mallinckrodt, Inc.

USPTO Granted Patents = 717

CIPO Patents = 113

EPO Patents = 136

Trademarks = 50

Forward Citations = 18,762

Loading Chart...

Loading Chart...

516 inventors (with patents filed for the assignee):

Gary Lee Cantrell (66 out of 67 patents)

Raghavan Rajagopalan (59 out of 118 patents)

Richard Bradley Dorshow (57 out of 95 patents)

4. Peter Xianqi Wang (54 out of 54 patents)

5. Joseph E Bugaj (52 out of 56 patents)

6. Samuel I Achilefu (50 out of 75 patents)

7. Frank M Fago (41 out of 89 patents)

8. Christopher W Grote (30 out of 30 patents)

9. Gary S Wagner (30 out of 42 patents)

10. Frank William Moser (30 out of 30 patents)

11. David W Berberich (28 out of 28 patents)

12. Tao Jiang (27 out of 55 patents)

13. Robert J Ziemba (22 out of 33 patents)

14. Michael E Fein (19 out of 79 patents)

15. Vernon D Ortenzi (19 out of 21 patents)

Core Competencies:

Toll-Like Receptor 9

Liposomal Cisplatin

Cancer Therapy

Intravenous Acetaminophen

Extended Release Compositions

Nanostructures for Imaging

Ocular Neovascular Disease

Morphinans Synthesis

Tamper Resistant Composition

Gastric Retentive Formulations

Phototherapy Compounds

Solid Dosage Forms

717 patents: Sort by Forward Citations

1. 11142502 - (+)-morphinans as antagonists of Toll-like receptor 9 and therapeutic uses thereof (2021-10-12),

2. 10604488 - (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof (2020-03-31),

3. 10383823 - Liposomal cisplatin compositions for cancer therapy (2019-08-20),

4. 10363251 - (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof (2019-07-30),

5. 10213385 - Combinational liposome compositions for cancer therapy (2019-02-26),

6. 10039716 - Liposomal cisplatin compositions for cancer therapy (2018-08-07),

7. 9987238 - Reduced dose intravenous acetaminophen (2018-06-05),

8. 9914695 - Two-step process for preparing 3-substituted phenylalkylamines (2018-03-13),

9. 9856251 - Substituted berbines and processes for their synthesis (2018-01-02),

10. 9766152 - Medicament sachet leak testing system (2017-09-19),

11. 9730885 - Extended release, abuse deterrent pharmaceutical compositions (2017-08-15),

12. 9717686 - Combinational liposome compositions for cancer therapy (2017-08-01),

13. 9713592 - Matrix-based pulse release pharmaceutical formulation (2017-07-25),

14. 9662387 - Functional, cross-linked nanostructures for tandem optical imaging and therapy (2017-05-30),

15. 9629837 - Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia (2017-04-25),

Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and commercializes branded and generic pharmaceutical products, as well as active pharmaceutical ingredients. They focus on therapies for autoimmune and rare diseases, including neuroscience, nephrology, pulmonology, immunology, and neonatology. With a commitment to innovation, Mallinckrodt strives to improve the lives of patients around the world.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

717 Patents

#1 in Hazelwood, MO

#10 in Missouri

#686 in US

#1,362 in the World

Hazelwood, MO, United States of America

Mallinckrodt, Inc.

Forward Citations = 18,762

516 inventors:

Gary Lee Cantrell (66 out of 67 patents)

Raghavan Rajagopalan (59 out of 118 patents)

Richard Bradley Dorshow (57 out of 95 patents)

4. Peter Xianqi Wang (54 out of 54 patents)

5. Joseph E Bugaj (52 out of 56 patents)

Please report any incorrect information to support@idiyas.com

Loading…